Volume 23 Issue 3, March 2024

The CACHE hit-finding competition highlights the potential of AI to identify small molecules that bind to hard-to-drug targets — and the long road ahead for these computational screening approaches.

This Review discusses the mechanisms that regulate stabilization of hypoxia-inducible factors (HIFs), and the pharmacological strategies to activate or inhibit HIFs in diseases such as ischaemia, inflammation, cancer, retinal neovascularization and pulmonary hypertension.

The TAM tyrosine kinase receptors TYRO3, AXL and MERTK regulate tissue and immune homeostasis. This Review discusses how their aberrant signalling is linked to diseases such as cancer, fibrosis and viral infection, and surveys the therapeutic landscape of TAM receptor inhibitors in preclinical and clinical development.

Several challenges hamper the translation of preclinical drug discovery efforts into safe and effective therapies for psychiatric disorders. In their Perspective, Khodosevich and colleagues highlight differences between drug targets in animal models and those in patients as a key reason for failed clinical studies. They present a framework that integrates single-cell and spatial omics data to overcome this loss in translation, which they hope will assist the development of new drugs for diseases such as schizophrenia and major depressive disorder.

Explore the latest progress in oncology drug development from both our company profiles and landscape feature that reviews the re-ignited interest in radiopharmaceuticals.

Learn about the fast-moving advances in molecular diagnostics and precision medicine from our profiling companies and landscape feature.